Security record · archived quarter
CRVS
Corvus Pharmaceuticals, Inc. · Healthcare · Biotechnology
14Tracked holders
0Δ holders
18.71MShares held
$137.91MReported value
+2New positions
−2Exits
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +1.5% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +6 | 34.72M | $518.70M | +11 | −5 |
| Q1 2026 | 64 | +8 | 30.80M | $450.00M | +15 | −7 |
| Q4 2025 | 56 | +2 | 25.04M | $192.77M | +2 | n/a |
| Q3 2025 | 14 | 0 | 18.71M | $137.91M | +2 | −2 |
| Q2 2025 | 11 | -1 | 17.31M | $69.23M | +1 | −2 |
| Q1 2025 | 9 | +2 | 6.14M | $19.53M | +2 | n/a |
| Q4 2024 | 7 | -1 | 4.46M | $23.85M | n/a | −1 |
| Q3 2024 | 7 | 0 | 7.32M | $38.63M | n/a | n/a |
| Q2 2024 | 7 | n/a | 7.37M | $13.41M | n/a | n/a |
Who holds it · Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 6.45M | -8.3% | $47.57M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 4.71M | +11.1% | $34.72M | 0.0% | ▲ Add | 2 | SEC ↗ ×8 |
| 3 | The Vanguard Group ✦ (passive) | 3.47M | +5.8% | $25.59M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 4 | Geode Capital Management ✦ (passive) | 1.46M | +7.0% | $10.74M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (passive) | 1.01M | +51.4% | $7.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Morgan Stanley ✦ | 617.22K | n/a | $4.55M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 7 | Goldman Sachs Group ✦ | 445.67K | n/a | $3.28M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 203.36K | -9.2% | $1.50M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 9 | Wellington Management ✦ | 180.18K | +76.0% | $1.33M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 10 | JPMorgan Chase ✦ | 64.46K | n/a | $475,100 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Citadel Advisors ✦ | 42.77K | New | $315,185 | 0.0% | New | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 32.41K | +23.2% | $239,000 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 25.57K | New | $188,488 | 0.0% | New | 1 | SEC ↗ |
| 14 | Fidelity (FMR) ✦ | 1.47K | +529.1% | $10,851 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Citadel Advisors | $315,185 | 0.0% |
| D. E. Shaw & Co. | $188,488 | 0.0% |
Exited
| Marshall Wace | $806,604 | was 0.0% |
| Renaissance Technologies | $660,752 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 163 holders, 69.83M shares, $976.09M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2025 ·
Methodology ·
Get this via the API